What do the trials say about cagrilintide dosage?
Every vial at a glance.
| Vial | 1 mL of water | 2 mL of water |
|---|---|---|
| 5 mg | 5 mg/mL: 0.6 mg is 12 units, 1.2 mg is 24 units, 2.4 mg is 48 units | 2.5 mg/mL: 0.6 mg is 24 units, 1.2 mg is 48 units, 2.4 mg is 96 units |
| 10 mg | 10 mg/mL: 0.6 mg is 6 units, 1.2 mg is 12 units, 2.4 mg is 24 units | 5 mg/mL: 0.6 mg is 12 units, 1.2 mg is 24 units, 2.4 mg is 48 units |
Doses in the cagrilintide trials
The vial table is arithmetic only: neither the sources nor the logged rows give a cagrilintide vial, and the doses are ones the trials gave. No cagrilintide label, regulator dosing document or labelled strength turned up in the searches, so every dose here is one a trial gave.
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Lau et al. 2021, phase 2 dose-finding2 | Once-weekly cagrilintide 0.3, 0.6, 1.2, 2.4 or 4.5 mg, against once-daily liraglutide 3.0 mg or placebo | 706 adults without diabetes enrolled1 | 26 weeks, including escalation of up to 6 weeks |
| Enebo et al. 2021, phase 1b, with semaglutide3 | Once-weekly cagrilintide 0.16, 0.30, 0.60, 1.2, 2.4 or 4.5 mg, or placebo, each with once-weekly semaglutide 2.4 mg | 96 randomised, aged 18-55 and otherwise healthy, 24 on placebo | 16 weeks escalation, 4 weeks at target, 5 weeks follow-up |
| Frias et al. 2023, phase 2 in type 2 diabetes4 | Once-weekly cagrilintide alone, against CagriSema or semaglutide, all escalated to 2.4 mg | 92 randomised, 30 on cagrilintide | 32 weeks |
| REDEFINE 1, Garvey et al. 202556 | Once-weekly cagrilintide 2.4 mg alone or with semaglutide 2.4 mg, against semaglutide 2.4 mg alone or placebo | 3417 adults without diabetes randomised, 302 on cagrilintide alone | 68 weeks, including 16 weeks of escalation |
| REDEFINE 2, Davies et al. 20257 | Once-weekly cagrilintide-semaglutide (2.4 mg each), against placebo | 1206 adults with type 2 diabetes randomised, 904 on the combination | 68 weeks |
Is there a label or a labelled strength?
Searches of DailyMed, ClinicalTrials.gov and PubMed returned no cagrilintide label, regulator dosing document or labelled strength. In its release, Novo Nordisk says it submitted CagriSema, cagrilintide 2.4 mg with semaglutide 2.4 mg, to the FDA as a once-weekly injection for adults with obesity.8 The maker's release also says CagriSema is not approved.8
No Milligram figure for cagrilintide is printed, because none was usable at the reporting floor.
How the doses were stepped up
In the phase 2 registry results, the 2.4 mg arm received 0.6 mg at week 0, 1.2 mg at week 2, then 2.4 mg from week 4 to week 26.1 The 4.5 mg arm received 0.6 mg at week 0, 1.2 mg at week 2 and 2.4 mg at week 4, then 4.5 mg from week 6 to week 26.1
The phase 1b trial by Enebo et al. (2021), in 96 people, co-escalated cagrilintide and semaglutide 2.4 mg in 4-week intervals to the target dose over 16 weeks, then gave the target dose for 4 weeks.3 The REDEFINE 1 registry entry (NCT05567796) gives a 16-week dose escalation before 52 weeks of maintenance in both the combination arm and the cagrilintide-alone arm, and the mg per step is not in the saved text.6 The authors of the single-dose kidney and liver impairment studies say they chose 0.6 and 0.9 mg, lower than the 2.4 mg dose in clinical development, because higher doses may be associated with gastrointestinal adverse effects, in particular nausea and vomiting, and require dose escalation to be attained.9
Route and injection site
The phase 2 trial gave cagrilintide as once-weekly subcutaneous self-injections, using a NovoPen 4 pen-injector.21 The phase 2 registry entry says the injection went into a skin fold in the stomach, thigh or upper arm.1 The phase 1b registry entry places the injection in a lifted fold of abdominal skin, and in the kidney and liver impairment studies qualified site staff gave a single 0.6 mg or 0.9 mg dose in an abdominal skinfold with a NovoPen 4.109
Mixing, concentration and storage
The phase 2 trial and the kidney and liver impairment studies gave cagrilintide with a NovoPen 4 pen-injector,19 and the sources searched give no powder, water volume, pH, mg per mL concentration or storage condition for the product. With no sourced vial strength and no logged vial, the vial table is arithmetic only, and no worked syringe example or preset calculator default is shown.
The mixing guide covers the general steps, and the cagrilintide calculator works a sum from any vial strength entered.
Combining cagrilintide with tirzepatide or retatrutide
Searches of the trial registry and PubMed found no human trial of cagrilintide combined with retatrutide or tirzepatide. The registry lists three phase 3 trials that compare CagriSema with tirzepatide (NCT06221969, NCT06131437 and NCT06534411) rather than combine them, and the only PubMed result with retatrutide is a study in rats. The dosing of each partner drug is in the semaglutide, tirzepatide and retatrutide guides, and the class is in GLP-1 and incretin. More on cagrilintide itself is on its compound page.
References
- ClinicalTrials.gov. NCT03856047: Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. 2023. clinicaltrials.gov
- PubMed. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. 2021. pubmed.ncbi.nlm.nih.gov
- PubMed. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. 2021. pubmed.ncbi.nlm.nih.gov
- PubMed. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. 2023. pubmed.ncbi.nlm.nih.gov
- PubMed. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. 2025. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT05567796: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight. 2026. clinicaltrials.gov
- PubMed. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. 2025. pubmed.ncbi.nlm.nih.gov
- Novo Nordisk (BioSpace). Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management. biospace.com
- PMC. Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. 2026. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT03600480: A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese. 2020. clinicaltrials.gov